ABSTRACT: Background. Cancer stem cells (CSCs) represent a subpopulation of cells responsible for tumor growth. Their role in head and neck squamous cell carcinoma (HNSCC) tumorigenesis and metastasis remains uncertain. Methods. Wound healing and an orthotopic animal model were used to study cells expressing the CSC phenotype (CD44 high and aldehyde dehydrogenase [ALDH] 1 ) and assess mobility, tumorigenesis, and metastasis. A prospective collection of 40 patient-derived primary HNSCC specimens were analyzed for CSC-proportion compared to clinical variables. Results. CSCs exhibited significantly faster wound closure and greater tumorigenesis and regional metastasis in vivo than non-CSCs. In primary patient tumors, size and advanced stage were correlated with elevated proportion of CSCs, however, not with survival. Conclusion. HNSCC stem cells mediate tumorigenesis and regional metastasis in vivo. In primary patient tumors, CSC-proportion was associated with tumor size and stage, but not with metastatic spread or survival. CSC burden alone may only represent a minor variable in understanding CSCs and metastasis.
INTRODUCTION
In the stochastic model of tumorigenesis, all cancer cells in a tumor population are capable of initiating tumor growth. The cancer stem cell (CSC) theory of tumorigenesis has recently gained popularity because of identification of a rare subset of cells, CSCs, with the ability for self-renewal, regeneration of a heterogeneous tumor cell population, and the ability to initiate tumors in vivo. The CSC theory holds that this subpopulation of cells are responsible for tumor growth and spread, whereas non-CSCs have limited capacity for regeneration of progeny or the ability to recapitulate a tumor. 1 Head and neck squamous cell carcinoma (HNSCC) affects over 40,000 Americans with 11,000 dying annually. 2 Regional lymphatic metastasis predisposes patients to the development of distant metastasis, effectively reducing survival rates by 50%. [3] [4] [5] [6] Despite advances in treatment, overall survival remains static. 2 Regional and distant metastases make up a considerable proportion of the treatment failures. 6 It is important to study factors associated with cancer spread to develop more effective diagnostic techniques and to identify therapeutic targets. Subpopulations of tumor cells with highly tumorigenic behavior can be identified in HNSCC based on the cellular markers CD44 and aldehyde dehydrogenase (ALDH). [7] [8] [9] [10] [11] CSCs have been identified in solid tumors, including breast, prostate, and pancreatic carcinoma. [11] [12] [13] We have previously demonstrated that a subset of HNSCC cells that express CD44 and ALDH have increased self-renewal, tumorigenicity, and the ability to recapitulate a heterogeneous tumor compared with cells without these markers in a flank injection mouse model. 8, 9 Cancer cells without these markers had limited or no tumorigenic potential. Additional work using a mouse tail vein injection model of CSCmediated metastasis demonstrated that HNSCC cells expressing CD44 high and ALDH 1 have a greater capacity to colonize the lungs compared to CD44 low and ALDH -tumor cells, which rarely if ever lead to successful lung colonization. 14 In addition, in vitro experiments have shown that HNSCC stem cells have increased motility and invasive characteristics in vitro compared to non-CSCs. However, spontaneous metastasis from tumors initiated by head and neck CSCs has not been shown. CSCs may play a key role in metastasis and may serve as a novel target for therapy. CSCs are thought to be slowly replicating cells that have innate chemotherapy and radiation resistance mechanisms. That behavior is a plausible mechanism for treatment failures. 12, 16 Development of a physiologic model of metastasis using CSCs is vital to demonstrate the role of CSCs in metastasis and understand the mechanisms of metastasis. More importantly, such a model can be used to develop novel strategies toward cancer therapy. In this article, we will test the hypotheses that (1) CSCs have a greater migratory rate compared to non-CSCs in vitro, (2) CSCs have a greater capacity for tumorigenesis and spontaneous metastasis using an orthotopic tip of the tongue mouse model, and (3) CSC enrichment is associated with metastasis and outcome.
MATERIALS AND METHODS

Patient data and tumor collection
Approval for use of patient data and specimen collection were approved by the University of Michigan's Institutional Review Board and all patients signed written informed consent for the study as part of the University of Michigan Head and Neck Specialized Program of Research Excellence. Forty patients with HNSCC were prospectively collected from 2007 to 2012 (mean age, 57.5 years; M:F ratio, 25:15; median follow-up, 0.8 years). Primary tumors (31 oral cavity, 8 laryngeal, 1 oropharyngeal) were harvested directly from tumor resection specimens. Tumor specimens were taken directly from the operating room and placed in 10% Dulbecco modified Eagle's Medium (DMEM) with 2% calf serum with amphotericin-B. Tumors were then cut into fine pieces with a scalpel and subjected to 2 hours of digestion with collagenase-hyaluronidase enzyme. Specimens were then placed into cell culture flasks with 10% DMEM and left undisturbed for 48 hours in a cell culture incubator. Cells were sorted by flow cytometry for CD44 expression. Tumor CSC enrichment was determined based on the percentage of tumor specimen cells expressing high levels (top 1%) of CD44 based on flow. CD44 expression percentage quartiles were then identified to categorize tumor specimens for analysis. CSC enrichment and clinical covariates (T and N classification, American Joint Committee on Cancer [AJCC] stage, age, tobacco use, perineural invasion [PNI], distant metastasis, tumor size, and tumor depth) were analyzed. Kaplan-Meier survival statistics were used to evaluate overall survival (OS), diseasespecific survival (DSS), and disease-free interval.
Cell lines and cell culture
UM-SCC-47 and UM-SCC-103 are well-established HNSCC cell lines derived from advanced stage oral cavity squamous cell carcinomas. 17, 18 Both cell lines were transfected with a luciferase cassette (luc1) for bioluminescence imaging, and were grown as previously described to 70% to 80% confluency, trypsinized, and sorted by flow cytometry for injection or plated for wound healing assays. 14 
Flow cytometry
CSCs and non-CSCs were identified and sorted by flow cytometry based on cellular expression patterns of CD44 and ALDH, as reported previously. [7] [8] [9] 14 ALDH activity was identified in the UM-SCC-47-luc1 and UM-SCC-103-luc1 cancer cell line using the ALDEFLUOR substrate in accord with the manufacturer's protocol (StemCo Biomedical, Durham, NC). Specimens being analyzed for ALDH activity were then counterstained with anti-CD44 (allophycocyanin conjugated; BD Pharmingen, San Diego, CA) at the appropriate dilution. Nonviable cells are eliminated using 4 0 ,6-diamidino-2-phenylindole (DAPI; BD Pharmingen). The specific flow cytometry gates for ALDH 1 cells were set using a control sample of isolated tumor cells in which ALDH activity was inhibited with diethylaminobenzaldehyde. Cells expressing CD44 were identified using a fluorescent conjugated anti-CD44 antibody (allophycocyanin conjugated, mouse antihuman, clone G44-26; BD Pharmingen) at a 1:50 dilution for 15 to 20 minutes. Subsequent flow cytometry runs were used to identify populations of cells with positive ALDH activity (ALDH 1 ), negative ALDH activity (ALDH -) (Supplemental Figure 1A and 1B, online only), and cells that express high levels of CD44 (CD44 high ) and low levels of CD44 (CD44 low ) (Supplemental Figure 1C and 1D, online only). For double sorts using both CD44 and ALDH, CD44 expression was identified first followed by subsequent ALDH activity. Cells with CD44 high /ALDH 1 were analyzed as CSC and CD44 low /ALDH -were analyzed as non-CSCs.
For the wound healing assay, UM-SCC-47-luc1 and UM-SCC-103-luc1 were sorted by flow cytometry, as described above for CD44 activity. Sorted cells (6 3 10 4 cells/well) were then placed into 24-well culture plates with 10% Dulbecco modified Eagle's medium and allowed to grow to 90% to 100% confluency. A 200 uL pipette tip was then used to make 2 parallel wounds per well. Cells were then observed and the area of the wound was measured at time 0, 9, 15, 18, 20, 24, 26 , and 28 hours. The area of the open wound was calculated using the NIH ImageJ free software analysis. 19 Percent closure was calculated based on the area of the wound at the times of interest divided by the area of time 0 for each wound. Time to 100% closure of the wound and mean percent closure at each time point were measured.
Orthotopic mouse model
Approvals for the use of the animal model and for collection of cancer specimens were obtained through the University of Michigan's Committee on Use and Care of Animals and the Institutional Review Board, respectively. Six to 8-week-old NOD/SCID mice were anesthetized with 30-100 mg/kg ketamine and 10 mg/kg xylazine intraperitoneal injections. UM-SCC 47 cells were then injected into the tip of the tongue submucosally. The range of cell numbers injected was 500-1 3 10 5 sorted and unsorted cells. The animals were observed for primary tumor growth in the tip of the tongue and for regional metastasis using bioluminescence. 10 Evaluation of successful tumor placement was determined by bioluminescence imaging on postinjection day number 1.
Tumor growth at the primary site and metastasis was confirmed by clinical palpation and bioluminescence imaging. Growth of the primary tumors and metastases were monitored weekly for up to 12 weeks by measuring tumor diameters with bioluminescence imaging. A partial glossectomy was performed at 14 to 28 days after injection to reduce tumor burden and improve the animal's ability to tolerate an oral diet and reduce upper airway obstruction. 20 Glossectomy specimens were taken for histologic analysis.
The animals were euthanized and histologic analysis of all tumors was performed to assess gross and histologic evidence of primary tumor growth, to confirm recapitulation of a heterogeneous tumor, confirm bioluminescence imaging regional or pulmonary metastasis, and to evaluate for renewal of CSCs based on flow cytometry. All histology slides were reviewed by a head and neck pathologist (J.B.M.). Outcomes of interest were rate of tumorigenesis (bioluminescence imaging intensity at weekly intervals), time to regional metastasis (time from injection to first identifiable metastasis by bioluminescence imaging), rate of metastatic growth (bioluminescence imaging intensity of regional metastasis at weekly intervals), and development of distant metastasis (time from injection to identification of distant metastasis by bioluminescence imaging). 21 
Luciferase transfection and bioluminescent imaging
The cell lines used in this study were transfected with luciferase to provide in vivo imaging to assess potential metastasis, as previously described. [7] [8] [9] 14 Mice were anesthetized with isofluorane and placed in the bioluminescent imaging machine to evaluate primary tumor growth and metastasis based on total number of photons/second. 22 To control for background variation, a ratio of tumor region of interest/background control were calculated and recorded to assess for growth.
Primary tumor growth and metastasis in the luciferasetransfected CSC lines injected into the mouse model was monitored with weekly bioluminescence imaging. An area around the tumor and metastasis as demonstrated by bioluminescence imaging was observed and a region of interest was defined around the tumor luminescence. Total and average photons/second were recorded and standardized to background luminescence to quantify and analyze primary growth and regional metastasis for statistical analysis. 
Statistical analysis
Wound-healing assays were measured based on mean time to 100% closure and percent-closure at each individual time point. The t test was used to calculate differences between means. Outcome measures were bioluminescence imaging intensity (photons/second), intensity over time (days), and time to metastasis. Bioluminescence imaging intensity was measured as average photons/second over time and log-transformed for comparison. A mixed model approach was used to test differences in intensity and differences over time (days) between the CSC versus the non-CSC groups. Kaplan-Meier survival statistics were used to evaluate time to metastasis among CSCs and non-CSCs and an unsorted control group. Patients were grouped based on clinical covariates of interest and CD44 expression was calculated. The t test was used to calculate differences between means. Tumor size and CD44 expression were then analyzed as continuous values. Pearson's correlation was then used to calculate correlation coefficient between tumor size and CD44 expression. For survival analysis, CD44 expression was grouped into CD44 high and CD44 low groups based on percentile rank; 50th percentile was calculated as CD44 high and <50th percentile was calculated as CD44 low . Kaplan-Meier survival statistics were used to calculate OS (time from definitive cancer treatment to death of any cause), DSS (time from definitive treatment to death from disease), and disease-free interval (time from definitive treatment to recurrence of disease). Any p value < .05 was considered statistically significant.
RESULTS
In vitro analysis of cancer stem cell motility
To evaluate CSC mobility, wound healing assays were performed using CD44 high versus CD44 low cells isolated from UM-SCC-47-luc1 and UM-SCC-103-luc1 ( Figure  1A ). Figure 1B shows representative photographs of the wound healing assay for UM-SCC-47 and UM-SCC-103. Figure 1C 
Orthotopic mouse model: Tumorigenesis
An orthotopic mouse model was generated based on previous work by Sano and Myers.
18 UM-SCC-47-luc1, 1 3 10 5 unsorted cells were injected into the tip of the tongue in NOD/SCID mice (Figure 2A ). Tumor growth was measured by luminescence (photons/second) at the primary site and regional lymph nodes ( Figure 2B ). To estimate the relative bioluminescence per cell, a known number of UM-SCC-47-luc1 cells were examined for bioluminescence intensity in vitro. Primary tumor and lymph nodes were examined on hematoxylin-eosinstained sections to confirm the presence of squamous cell carcinoma ( Figure 2C) .
The relative capacity of CSCs and non-CSCs to generate tumors was compared using the orthotopic mouse model. Figure 4B and 4C ). Histologic analysis of the lymph nodes confirmed the bioluminescence imaging results and the development of spontaneous metastasis of squamous cell carcinoma (Figure 4D) .
A distant metastasis was detected by luminescence in a CD44
high /ALDH 1 mouse that could be kept alive for 71 days postinjection and 38 days postglossectomy. Bulky lymphadenopathy was seen by luminescence and confirmed by necropsy. Histologic analysis of the regional and distant lung metastasis confirmed spontaneous metastasis of squamous cell carcinoma ( Figure 5E ). A comparative CD44 low /ALDH -mouse that developed a primary tumor significantly delayed after injection was kept alive for a similar length of time and did not develop distant metastasis.
Patient outcomes and tumor CD44 high content
Mean CD44 high content of all 40 tumor specimens was 10.8% (range, 0% to 84.5%). There was no statistical difference in mean CD44 high content between subsites (oral cavity 12.6%, oropharynx 12.9%, and larynx 3.2%; p 5 .436; Figure 5A ). Mean CD44 content in primary tumors relative to regional metastasis, distant metastasis, stage, tumor size, and PNI was evaluated ( Figure 5B-5F ). Only stage and tumor size were significantly correlated with CD44 content. Advanced stage tumors (AJCC stage III/ IV) had significantly elevated CD44 content compared to early stage (AJCC stage I/II; 11.6% vs 1.2%; p 5 .002). Increased tumor size was associated with elevated CD44 content (p 5 .007). Tumor specimens from patients with regional metastases had higher CD44 high content compared to patient specimens without regional metastases; however, this was not statistically significant (12% vs 9.7%; p 5 .70). Tumor specimens from patients who had at least 2 years of follow-up were analyzed for association of CD44 enrichment and distant metastases. Patients who developed distant metastases had higher CD44 content compared to patient specimens without distant metastases; however, this was not statistically significant (10.2% vs 4.3%; p 5 .34). PNI is a known risk factor for regional metastasis. In patients with PNI, there were higher levels of CD44
high content compared to PNInegative specimens; however, there was no statistical correlation (10.2% and 4.3%; p 5 .32).
Analysis of patient survival outcomes relative to CD44 content was performed ( Figure 5G and 5H capacity for spontaneous regional and distant metastatic spread and growth compared to non-CSCs (CD44 low and CD44 low /ALDH -). This is an important step in defining the role of CSCs in metastasis and developing a model for future targeted stem cell therapy. In primary patient tumors, CSC enrichment in primary tumors is significantly associated with increased tumor size and tumor stage, whereas there were trends for association of CD44 high content with regional and distant metastasis and PNI. CD44 high content was not associated with long-term survival.
Work by others in breast, colorectal, and prostate cancers support our findings indicating that CSCs may play a critical role in tumorigenesis, treatment resistance, and metastasis. [11] [12] [13] 23 We initially sought to evaluate in vitro assays of cell migration via wound healing assay as a proxy to establish CSCs as a more aggressive subtype from a wound healing standpoint. CSCs seem to have a greater rate of wound closure compared to non-CSCs for both UM-SCC-47 and UM-SCC-103. To further validate the in vitro data, a more physiologic model was developed. In head and neck cancer, previous work by Prince et al 8 A common concern for the tail vein injection model is that the lung lesions represent tumor seeding or capillary entrapment rather than overt cancer metastasis and invasion. The tip of the tongue of the orthotopic mouse model addresses the ability for CSC recapitulation of heterogeneous tumors with significantly elevated tumorigenicity at the primary site and a significant ability to form spontaneous regional and distant metastasis.
We have shown that cells expressing high levels of CD44 alone or jointly with elevated ALDH activity have a greater ability to form primary tumors and regional metastasis compared to cells lacking these 2 markers. The development of regional metastasis in the CSC group further strengthens the argument that CSCs are an essential regulator and component of metastatic spread. The exact role of CD44 and ALDH in CSC pathophysiology remains unclear. CD44 is a cell surface receptor for the extracellular matrix molecule hyaluronan, with multiple established mechanisms for cancer growth and spread. Specifically, CD44 has been implicated as a cell surface receptor for cell-cell adhesion, cell-matrix adhesion, endothelial attachment and invasion, cell signal transmission, and potent mediator for cell proliferation. 24 Wang et al 24 were able to show that elevated CD44 was associated with worse survival. Over the last several years, its role as a CSC marker has been extensively studied. However, CD44 high may not identify all cells with CSC characteristics and has been shown to be a less selective marker of HNSCC than ALDH expression. 8 If sufficient numbers of CD44 low cells, such as the experiments in which 2.5 3 10 4 CD44 low non-CSCs could eventually yield tumor growth and regional metastasis over longer periods of time compared to the CD44 high CSC group, the addition of ALDH as a second marker for CSC identification can help demonstrate a more specific marker for CSC ability to form primary tumors and regional metastasis.
ALDH is a well-established marker for normal hematopoietic and nervous system stem cells. 25 In addition, ALDH activity has been a significant marker for breast CSCs. 11 Work by Clay et al 9 has shown that ALDH activity is associated with head and neck CSCs and may be a more specific marker for highly tumorigenic cancer cells. 8, 9 Although the in vitro wound-healing assay did not assess CD44 One of the weaknesses of this study was the potential for non-CSCs to form tumors and regional metastasis. The capacity for lymph node metastases for non-CSCs were identified and found to be significantly lower compared to CSCs. Despite attempts to isolate 100% CSCs and 100% non-CSCs, the current flow technology does not allow for complete cell expression or marker purity. One can hypothesize that the lymph node growth may represent the impurity of the non-CSC injections. Alternatively, non-CSCs may have a low metastatic potential. This question is interesting and requires future study, particularly given the heterogeneous nature of HNSCC.
Grossly, HNSCC is seen as a heterogeneous tumor with varied clinical outcomes. At the cellular level, it is possible that although CSCs may have the potential for metastatic spread, the CSC population in an individual tumor is highly heterogeneous and not all CSCs are capable of regional or distant metastasis. 26 Although size and stage were associated with enrichment of CD44 high cells, there was no statistical association with metastasis and survival. This suggests that increased enrichment of CD44 cells is associated with tumorigenesis, but not with metastasis and outcome. Limitations of the patient data are the number of patients studied. A larger study may identify associations between CD44 enrichment and metastasis and outcome. CD44 has several variants that are associated with survival outcomes. 24 Although the antibodies used for flow did not assess CD44-variants, it is very possible that CSC CD44-variant expression mediates metastatic potential. All animals injected with UM-SCC-47 had regional disease, whereas the patient population was not as clear based on CD44 expression. CD44 variants, as described by Wang et al, 24 may represent a vital variable with regard to metastatic capability. Future examination of CD44-variant expression within CSCs may further delineate metastatic expression signatures in CSCs. However, taken in context with the in vivo animal study findings that CSCs are necessary for metastasis; one could interpret the patient data to support the theory that a limited number of or even a single CSC is capable of forming metastases and that treatment failure or recurrence may be mediated by a small number of residual CSCs (Figure 6A) . Metastatic capacity may not be programmed into every CSC and it may be the continued accumulation of mutations or expression alterations that may activate the ability for particular CSCs to gain invasive capacity and to form metastasis. Identification of the CSC-metastatic genetic signature may yield the best chance for understanding the CSC-specific mechanisms of metastasis and for targeted treatment. Designing CSC-specific signatures and targets may provide novel insight into diagnostics and potentially novel treatment modalities ( Figure 6B) .
Overall, this study demonstrated the essential role CSCs have in tumorigenesis and, more importantly, as a vital component of the development of metastasis. The development of an animal model with the ability to recreate metastatic disease is an important step for understanding the biology of CSCs and metastatic disease, but more importantly allows for a model to test potential therapeutics targeting head and neck CSCs. Further studies to better define the role that CSCs have in tumorigenesis and metastasis will be critical to developing novel targets for therapy.
